SLC5A2 and hydrops fetalis: When pooled analysis was performed for RCTs with longer (>1 year) follow-up, SGLT-2 inhibitors reduced the risk of a composite of hospitalization for HF and CV death (HR [95 % CI] = 0.79 [0.71, 0.88], Pfix < 0.001; heterogeneity, P = 0.84, I2 = 0 %) but not the risk of all-cause death (OR [95 % CI] = 1.00 [0.87, 1.14], Pfix = 0.94; heterogeneity, P = 0.92, I2 = 0 %; supplemental Fig. 5).